Finch Therapeutics Group, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Finch Therapeutics Group, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Finch Therapeutics Group, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$4.83M, a 30.4% increase year-over-year.
  • Finch Therapeutics Group, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$14.2M, a 89.6% increase year-over-year.
  • Finch Therapeutics Group, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$74.8M, a 34.8% increase from 2022.
  • Finch Therapeutics Group, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$115M, a 97.1% decline from 2021.
  • Finch Therapeutics Group, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.2M, a 47.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$14.2M -$4.83M +$2.12M +30.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$16.3M -$3.88M +$58.5M +93.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-13
Q4 2023 -$74.8M -$3.04M +$24M +88.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$98.7M -$2.42M +$38M +94% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$137M -$6.95M +$15.8M +69.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$152M -$62.3M -$37.8M -154% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-13
Q4 2022 -$115M -$27M -$7.95M -41.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$107M -$40.4M -$30.4M -306% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$76.3M -$22.7M -$7.53M -49.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$68.7M -$24.6M -$10.6M -75.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$58.2M -$19.1M -$5.96M -45.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$52.2M -$9.96M +$135K +1.34% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$52.3M -$15.2M -$6.91M -83.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$45.4M -$14M -$6.08M -77% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$39.3M -$13.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$10.1M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$8.26M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$7.9M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.